Roche, PacBio to Develop NGS-based Clinical Dx in Potential $75M Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences today announced an agreement with Roche Diagnostics to develop diagnostic products based on PacBio's SMRT technology.

Including upfront, milestone, and supply payments, the deal is potentially worth more than $75 million to PacBio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.